Search Results for "Alnylam"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
Givosiran: Use in Pediatric Patients
Standard response letter on givosiran and pediatric use. This medical information response contains clinical data from the ENVISION study, ELEVATE registry, and published case reports.
Standard response letter on givosiran and pediatric use. This medical information response contains clinical data from the ENVISION study, ELEVATE registry, and published case reports.
Patisiran: Transitioning from Inotersen
Standard response letter on transitioning from an antisense oligonucleotide to patisiran.
Standard response letter on transitioning from an antisense oligonucleotide to patisiran.
Vutrisiran: Cardiac Results from the HELIOS-A Study
Standard response letter on vutrisiran and exploratory cardiac results from the HELIOS-A study evaluating efficacy and safety of vutrisiran in patients with polyneuropathy of hATTR.
Standard response letter on vutrisiran and exploratory cardiac results from the HELIOS-A study evaluating efficacy and safety of vutrisiran in patients with polyneuropathy of hATTR.
Patisiran: Dosing Schedule
Standard response letter on patisiran and the dosing schedule used in clinical trials.
Standard response letter on patisiran and the dosing schedule used in clinical trials.
Lumasiran: Clinical Pharmacology
Standard Response Letter on lumasiran and its pharmacokinetic and pharmacodynamic properties.
Standard Response Letter on lumasiran and its pharmacokinetic and pharmacodynamic properties.
Zilebesiran: KARDIA-2 Study
Standard response letter on zilebesiran and the KARDIA-2 study, a phase 2 study evaluating the efficacy and safety of zilebesiran as add-on therapy in patients with hypertension not adequately controlled by a standard-of-care antihypertensive medication including diuretic (indapamide), CCB (amlodipine), or ARB (olmesartan).
Standard response letter on zilebesiran and the KARDIA-2 study, a phase 2 study evaluating the efficacy and safety of zilebesiran as add-on therapy in patients with hypertension not adequately controlled by a standard-of-care antihypertensive medication including diuretic (indapamide), CCB (amlodipine), or ARB (olmesartan).
Vutrisiran: Survival and Mortality
Standard response letter on mortality and survival data from the HELIOS studies of vutrisiran.
Standard response letter on mortality and survival data from the HELIOS studies of vutrisiran.